Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule

Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a marker of various cancers and mesenchymal stem cells, is involved in melanoma metastasis. We have exploited a secreted NH(2)-terminal fragment, sALCAM, to test the hypothesis that ALCAM coordinates tissue growth and cell migration. Ove...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Vol. 68; no. 10; p. 3671
Main Authors: van Kilsdonk, Jeroen W J, Wilting, Roel H, Bergers, Mieke, van Muijen, Goos N P, Schalkwijk, Joost, van Kempen, Léon C L T, Swart, Guido W M
Format: Journal Article
Language:English
Published: United States 15.05.2008
Subjects:
Activated-Leukocyte Cell Adhesion Molecule - chemistry
Animals
Basement Membrane - metabolism
Cell Adhesion
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Humans
Leukocytes - cytology
Melanoma - pathology
Melanoma - therapy
Mice
Mice, Nude
Neoplasm Invasiveness
Neoplasm Metastasis
Neural Cell Adhesion Molecule L1 - metabolism
Protein Structure, Tertiary
ISSN:1538-7445, 1538-7445
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a marker of various cancers and mesenchymal stem cells, is involved in melanoma metastasis. We have exploited a secreted NH(2)-terminal fragment, sALCAM, to test the hypothesis that ALCAM coordinates tissue growth and cell migration. Overexpression of sALCAM in metastatic melanoma cells disturbed clustering of endogenous ALCAM and inhibited activation of matrix metalloproteinase-2 (MMP-2). Exposure of HT1080 fibrosarcoma cells to sALCAM similarly inhibited MMP-2, suggesting a broader effect on ALCAM-positive tumor cells. In contrast to the previously reported, promotive effects of an NH(2)-terminally truncated, transmembrane variant (DeltaN-ALCAM), sALCAM impaired the migratory capacity of transfected cells in vitro, reduced basement membrane penetration in reconstituted human skin equivalents, and diminished metastatic capacity in nude mice. Remarkably, L1 neuronal cell adhesion molecule (L1CAM/CD171), another progression marker of several cancers including melanoma, was suppressed upon sALCAM overexpression but was up-regulated by DeltaN-ALCAM. The partially overlapping and opposite effects induced by alternative strategies targeting ALCAM functions collectively attribute an integrative role to ALCAM in orchestrating cell adhesion, growth, invasion, and proteolysis in the tumor tissue microenvironment and disclose a therapeutic potential for sALCAM.
AbstractList Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a marker of various cancers and mesenchymal stem cells, is involved in melanoma metastasis. We have exploited a secreted NH(2)-terminal fragment, sALCAM, to test the hypothesis that ALCAM coordinates tissue growth and cell migration. Overexpression of sALCAM in metastatic melanoma cells disturbed clustering of endogenous ALCAM and inhibited activation of matrix metalloproteinase-2 (MMP-2). Exposure of HT1080 fibrosarcoma cells to sALCAM similarly inhibited MMP-2, suggesting a broader effect on ALCAM-positive tumor cells. In contrast to the previously reported, promotive effects of an NH(2)-terminally truncated, transmembrane variant (DeltaN-ALCAM), sALCAM impaired the migratory capacity of transfected cells in vitro, reduced basement membrane penetration in reconstituted human skin equivalents, and diminished metastatic capacity in nude mice. Remarkably, L1 neuronal cell adhesion molecule (L1CAM/CD171), another progression marker of several cancers including melanoma, was suppressed upon sALCAM overexpression but was up-regulated by DeltaN-ALCAM. The partially overlapping and opposite effects induced by alternative strategies targeting ALCAM functions collectively attribute an integrative role to ALCAM in orchestrating cell adhesion, growth, invasion, and proteolysis in the tumor tissue microenvironment and disclose a therapeutic potential for sALCAM.
Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a marker of various cancers and mesenchymal stem cells, is involved in melanoma metastasis. We have exploited a secreted NH(2)-terminal fragment, sALCAM, to test the hypothesis that ALCAM coordinates tissue growth and cell migration. Overexpression of sALCAM in metastatic melanoma cells disturbed clustering of endogenous ALCAM and inhibited activation of matrix metalloproteinase-2 (MMP-2). Exposure of HT1080 fibrosarcoma cells to sALCAM similarly inhibited MMP-2, suggesting a broader effect on ALCAM-positive tumor cells. In contrast to the previously reported, promotive effects of an NH(2)-terminally truncated, transmembrane variant (DeltaN-ALCAM), sALCAM impaired the migratory capacity of transfected cells in vitro, reduced basement membrane penetration in reconstituted human skin equivalents, and diminished metastatic capacity in nude mice. Remarkably, L1 neuronal cell adhesion molecule (L1CAM/CD171), another progression marker of several cancers including melanoma, was suppressed upon sALCAM overexpression but was up-regulated by DeltaN-ALCAM. The partially overlapping and opposite effects induced by alternative strategies targeting ALCAM functions collectively attribute an integrative role to ALCAM in orchestrating cell adhesion, growth, invasion, and proteolysis in the tumor tissue microenvironment and disclose a therapeutic potential for sALCAM.Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a marker of various cancers and mesenchymal stem cells, is involved in melanoma metastasis. We have exploited a secreted NH(2)-terminal fragment, sALCAM, to test the hypothesis that ALCAM coordinates tissue growth and cell migration. Overexpression of sALCAM in metastatic melanoma cells disturbed clustering of endogenous ALCAM and inhibited activation of matrix metalloproteinase-2 (MMP-2). Exposure of HT1080 fibrosarcoma cells to sALCAM similarly inhibited MMP-2, suggesting a broader effect on ALCAM-positive tumor cells. In contrast to the previously reported, promotive effects of an NH(2)-terminally truncated, transmembrane variant (DeltaN-ALCAM), sALCAM impaired the migratory capacity of transfected cells in vitro, reduced basement membrane penetration in reconstituted human skin equivalents, and diminished metastatic capacity in nude mice. Remarkably, L1 neuronal cell adhesion molecule (L1CAM/CD171), another progression marker of several cancers including melanoma, was suppressed upon sALCAM overexpression but was up-regulated by DeltaN-ALCAM. The partially overlapping and opposite effects induced by alternative strategies targeting ALCAM functions collectively attribute an integrative role to ALCAM in orchestrating cell adhesion, growth, invasion, and proteolysis in the tumor tissue microenvironment and disclose a therapeutic potential for sALCAM.
Author Bergers, Mieke
van Kilsdonk, Jeroen W J
Schalkwijk, Joost
van Muijen, Goos N P
Swart, Guido W M
van Kempen, Léon C L T
Wilting, Roel H
Author_xml – sequence: 1
  givenname: Jeroen W J
  surname: van Kilsdonk
  fullname: van Kilsdonk, Jeroen W J
  organization: Department of Biomolecular Chemistry 271, Institute for Molecules and Materials and Nijmegen Centre for Molecular Life Sciences, Faculty of Science, Radboud University Nijmegen
– sequence: 2
  givenname: Roel H
  surname: Wilting
  fullname: Wilting, Roel H
– sequence: 3
  givenname: Mieke
  surname: Bergers
  fullname: Bergers, Mieke
– sequence: 4
  givenname: Goos N P
  surname: van Muijen
  fullname: van Muijen, Goos N P
– sequence: 5
  givenname: Joost
  surname: Schalkwijk
  fullname: Schalkwijk, Joost
– sequence: 6
  givenname: Léon C L T
  surname: van Kempen
  fullname: van Kempen, Léon C L T
– sequence: 7
  givenname: Guido W M
  surname: Swart
  fullname: Swart, Guido W M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18483249$$D View this record in MEDLINE/PubMed
BookMark eNpNkEtPwzAQhC1URB_wE0A-cUvZOHbtHquKl1TBBc7Vxt6IQGKX2KnUfw-BInHa0Wi-1e5M2cgHT4xd5jDPc2VuAMBkSmoxX6-eMtCZ0gt9wia5KkympVSjf3rMpjG-fyMqB3XGxrmRphByOWFulRL5HlMdPA8Vb6lBH1rktd9jHMzywJFHsh0lcnyPXY0-DVG0qd7jYDbUfwR7SMQtNQ1H90Y_aBsasn1D5-y0wibSxXHO2Ovd7cv6Ids83z-uV5vMStApc9qp0jjhpBEKXaEMGAANVi7KSqMubFmULi9EASShkmQRYFGqJS2VqUQlZuz6d--uC589xbRt6zichJ5CH7catFTD5zN2dQz2ZUtuu-vqFrvD9q8X8QWE4mkG
CitedBy_id crossref_primary_10_1007_s11307_011_0500_8
crossref_primary_10_1111_j_1471_4159_2012_07658_x
crossref_primary_10_1016_j_yexmp_2020_104443
crossref_primary_10_1016_j_humpath_2017_04_032
crossref_primary_10_1089_scd_2021_0059
crossref_primary_10_1097_CMR_0b013e32833d8d70
crossref_primary_10_1242_bio_061729
crossref_primary_10_1007_s10549_010_1219_y
crossref_primary_10_1097_JTO_0b013e31824af2db
crossref_primary_10_1002_stem_1665
crossref_primary_10_1002_jso_21756
crossref_primary_10_1158_0008_5472_CAN_15_1322
crossref_primary_10_3390_cancers13205187
crossref_primary_10_1038_s41388_020_01485_8
crossref_primary_10_1158_0008_5472_CAN_12_3686
crossref_primary_10_1007_s13277_014_2905_x
crossref_primary_10_1007_s00018_012_1132_0
crossref_primary_10_1016_j_jss_2012_02_013
crossref_primary_10_1371_journal_pone_0039018
crossref_primary_10_1007_s00262_010_0892_3
crossref_primary_10_1038_jid_2010_149
crossref_primary_10_1002_ijc_26377
crossref_primary_10_2217_epi_2021_0155
crossref_primary_10_1002_cbf_3525
crossref_primary_10_1016_j_ejcb_2009_11_026
crossref_primary_10_1038_s41598_018_21467_x
crossref_primary_10_1523_JNEUROSCI_2215_09_2009
crossref_primary_10_1016_j_jss_2011_06_002
crossref_primary_10_1002_ijc_24192
crossref_primary_10_1016_j_fsi_2023_108516
crossref_primary_10_1016_j_vaccine_2010_03_034
crossref_primary_10_3390_cells10061450
crossref_primary_10_1093_neuonc_nor202
crossref_primary_10_1038_mp_a004126_01
crossref_primary_10_1016_j_jss_2012_08_044
crossref_primary_10_1093_neuonc_not222
crossref_primary_10_2217_mmt_14_23
crossref_primary_10_1007_s00432_015_1973_7
crossref_primary_10_1002_ijc_27948
crossref_primary_10_3892_or_2013_2627
crossref_primary_10_1016_j_semcdb_2009_08_005
crossref_primary_10_1038_bjc_2011_219
crossref_primary_10_1038_jid_2011_487
crossref_primary_10_1074_jbc_M111_237297
crossref_primary_10_1586_era_10_153
crossref_primary_10_1111_pcmr_12172
crossref_primary_10_1038_s41388_020_01419_4
crossref_primary_10_3892_or_2015_3818
crossref_primary_10_7717_peerj_3754
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/0008-5472.CAN-07-5767
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7445
ExternalDocumentID 18483249
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-ET
.55
18M
29B
2WC
34G
39C
3O-
53G
5GY
5RE
5VS
6J9
8WZ
A6W
AAFWJ
AAJMC
ABOCM
ACGFO
ACIWK
ACPRK
ADBBV
ADCOW
AENEX
AETEA
AFFNX
AFHIN
AFOSN
AFRAH
AFUMD
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
C1A
CGR
CS3
CUY
CVF
DIK
DU5
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
MVM
NPM
OHT
OK1
P0W
P2P
PQQKQ
RCR
RHI
RNS
SJN
TR2
UDS
VH1
W2D
W8F
WH7
WOQ
X7M
XJT
YKV
YZZ
ZCG
7X8
ABUFD
ID FETCH-LOGICAL-c407t-d7d5b8d2d4825ad358080070c46bf7a73cb3bd13230e40f4eca006b59e958f2f2
IEDL.DBID 7X8
ISICitedReferencesCount 55
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000255933600020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1538-7445
IngestDate Sun Nov 09 13:52:05 EST 2025
Mon Jul 21 06:01:40 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c407t-d7d5b8d2d4825ad358080070c46bf7a73cb3bd13230e40f4eca006b59e958f2f2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 18483249
PQID 70745483
PQPubID 23479
ParticipantIDs proquest_miscellaneous_70745483
pubmed_primary_18483249
PublicationCentury 2000
PublicationDate 2008-May-15
20080515
PublicationDateYYYYMMDD 2008-05-15
PublicationDate_xml – month: 05
  year: 2008
  text: 2008-May-15
  day: 15
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer research (Chicago, Ill.)
PublicationTitleAlternate Cancer Res
PublicationYear 2008
SSID ssj0005105
Score 2.1660268
Snippet Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a marker of various cancers and mesenchymal stem cells, is involved in melanoma metastasis. We...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 3671
SubjectTerms Activated-Leukocyte Cell Adhesion Molecule - chemistry
Animals
Basement Membrane - metabolism
Cell Adhesion
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Humans
Leukocytes - cytology
Melanoma - pathology
Melanoma - therapy
Mice
Mice, Nude
Neoplasm Invasiveness
Neoplasm Metastasis
Neural Cell Adhesion Molecule L1 - metabolism
Protein Structure, Tertiary
Title Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule
URI https://www.ncbi.nlm.nih.gov/pubmed/18483249
https://www.proquest.com/docview/70745483
Volume 68
WOSCitedRecordID wos000255933600020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSwMxFA7VinhxX-qag9foLMkkA4KUYvFgSw8KvQ1ZsdjOVLtA_70vM1M8iQcvcwgTCHlLvrcjdAtswKR0MZE8TsBASQKinLHERVLqUFgaqbKJ6wvv98VwmA4a6GFdC-PTKtc6sVTUptDeR37P4a0DdB0_Tj-JnxnlY6v1AI0N1IwByHie5sOfXuGsSmAsRZpTyur6nZAJX74gCKM8uuu0-95TB6ib_44xy7emu_e_U-6j3Rpj4nbFFAeoYfNDtN2ro-hHyLTngJSrHt-4cHhixzIvJhKP8qX03jOsVljimUeUAEjxEuxpIID_1ZdBLKVfHNvFR6FXc4u97x9L827LrZNq3q49Rm_dp9fOM6mnLRANRt2cGG6YEiYyFIxGaXx4VPhmQJomynEgpVaxMmC8xoGlgaNWS5BYxVKbMuEiF52gzbzI7RnCLFEg6amNuOZUqFABKDOBU4mMUsAUuoVu1reXATf7Y8rcFotZtr6_FjqtCJBNq6YbGViioHxoev7n3gu0UyV1MBKyS9R0IMf2Cm3p5Xw0-7oumQS-_UHvGzrPxsE
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Attenuation+of+melanoma+invasion+by+a+secreted+variant+of+activated+leukocyte+cell+adhesion+molecule&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=van+Kilsdonk%2C+Jeroen+W+J&rft.au=Wilting%2C+Roel+H&rft.au=Bergers%2C+Mieke&rft.au=van+Muijen%2C+Goos+N+P&rft.date=2008-05-15&rft.eissn=1538-7445&rft.volume=68&rft.issue=10&rft.spage=3671&rft_id=info:doi/10.1158%2F0008-5472.CAN-07-5767&rft_id=info%3Apmid%2F18483249&rft_id=info%3Apmid%2F18483249&rft.externalDocID=18483249
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon